CN115040565B - Enema traditional Chinese medicine for reducing creatinine and preparation method and application thereof - Google Patents
Enema traditional Chinese medicine for reducing creatinine and preparation method and application thereof Download PDFInfo
- Publication number
- CN115040565B CN115040565B CN202210554029.9A CN202210554029A CN115040565B CN 115040565 B CN115040565 B CN 115040565B CN 202210554029 A CN202210554029 A CN 202210554029A CN 115040565 B CN115040565 B CN 115040565B
- Authority
- CN
- China
- Prior art keywords
- parts
- enema
- traditional chinese
- chinese medicine
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000792859 Enema Species 0.000 title claims abstract description 60
- 239000007920 enema Substances 0.000 title claims abstract description 60
- 229940095399 enema Drugs 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 title abstract description 32
- 229940109239 creatinine Drugs 0.000 title abstract description 16
- 230000001603 reducing effect Effects 0.000 title abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 50
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 28
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 21
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 14
- 235000005412 red sage Nutrition 0.000 claims abstract description 14
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 240000004980 Rheum officinale Species 0.000 claims description 20
- 235000008081 Rheum officinale Nutrition 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 241000245665 Taraxacum Species 0.000 description 19
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 241000237502 Ostreidae Species 0.000 description 14
- 235000020636 oyster Nutrition 0.000 description 14
- 238000005303 weighing Methods 0.000 description 12
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 244000132619 red sage Species 0.000 description 10
- 235000006533 astragalus Nutrition 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 241000045403 Astragalus propinquus Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 241000037740 Coptis chinensis Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 241000219061 Rheum Species 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000548230 Crassostrea angulata Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000173529 Aconitum napellus Species 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 229940023019 aconite Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000006368 chronic pyelonephritis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The application discloses an enema traditional Chinese medicine for reducing creatinine and a preparation method and application thereof. The traditional Chinese medicine for clysis comprises the following components in parts by weight: 28-32 parts of dandelion, 28-32 parts of red sage root and 14-16 parts of rhubarb. The preparation method is that the traditional Chinese medicine for clysis is used as raw material, decoction is reserved after water decoction and is used as enema, and the weight of the obtained enema is 1-3 times of that of the raw material. The traditional Chinese medicine enema provided by the application has the advantages of simple components, convenient preparation and mild medicine property, and has obvious creatinine reducing effect in the process of treating chronic kidney diseases and chronic renal failure.
Description
Technical Field
The application belongs to the technical field of traditional Chinese medicines, and particularly relates to an enema traditional Chinese medicine for reducing creatinine and a preparation method and application thereof.
Background
Chronic Kidney Disease (CKD) is a general term for the most chronic manifestation of kidney disease, such as glomerulonephritis, nephrotic syndrome, latent nephritis, pyelonephritis, allergic purpura nephritis, lupus erythematosus nephritis, etc., and can be classified into chronic kidney disease in addition to acute nephritis and acute inflammatory diseases of kidney such as acute urinary infection. In recent years, the incidence and prevalence of chronic kidney disease and the resulting Chronic Renal Failure (CRF) have increased significantly worldwide, and have become a non-negligible medical and social problem. Therefore, it is necessary to enhance early prevention and treatment of chronic renal failure. From clinical practice, if the traditional Chinese medicine is properly prepared in early and middle stages of chronic renal failure, symptoms can be obviously relieved or even eliminated, renal function indexes can be improved to different degrees, life quality can be improved, renal failure progress can be delayed, and life can be prolonged.
In the prior art, patent document CN114224941A discloses a traditional Chinese medicine composition for treating chronic renal failure and application thereof, and the raw material medicines of the composition comprise 28-32 parts of raw rhubarb, 28-32 parts of calcined oyster, 28-32 parts of red sage root, 13-17 parts of aconite, 28-32 parts of astragalus and 13-17 parts of medicated leaven, and the raw material medicines are decocted to prepare enema for treatment. Enema therapy is a method of administration which adopts a rectal administration mode, and can be rapidly absorbed into the large circulation through the rectal mucosa to exert the drug effect so as to treat systemic or local diseases. The enema therapy is more rapid and effective in temperature absorption of the effective components of the medicine, but the traditional Chinese medicine composition is complex in components, contains unprocessed aconite which is easy to stimulate intestinal mucosa, and can not only influence the curative effect but also cause other toxic and side effects after being directly decocted.
Disclosure of Invention
The application aims to solve the technical problem of providing an enema traditional Chinese medicine for reducing creatinine, and a preparation method and application thereof, wherein the enema traditional Chinese medicine has the advantages of simple raw material components, convenient preparation and mild medicine property, and has obvious creatinine reducing effect in the process of treating chronic kidney diseases and chronic renal failure.
In order to solve the technical problems, the application adopts the following technical scheme:
firstly, the application provides an enema traditional Chinese medicine for reducing creatinine.
The traditional Chinese medicine for clysis comprises the following components in parts by weight: 28-32 parts of dandelion, 28-32 parts of red sage root and 14-16 parts of rhubarb.
In at least one embodiment, the enema traditional Chinese medicine further comprises the following components in parts by weight: 11-13 parts of coptis chinensis.
In at least one embodiment, the enema traditional Chinese medicine further comprises the following components in parts by weight: 28-32 parts of oyster.
In at least one embodiment, the enema traditional Chinese medicine further comprises the following components in parts by weight: 28-32 parts of oyster and 45-55 parts of astragalus.
Secondly, the application also provides a preparation method of the traditional Chinese medicine enema.
The preparation method is that the traditional Chinese medicine for clysis is used as raw material, decoction is reserved after water decoction and is used as enema, and the weight of the obtained enema is 1-3 times of that of the raw material.
Finally, the application also provides application of the traditional Chinese medicine enema.
In particular to application of the traditional Chinese medicine enema in preparing medicines for treating chronic renal failure.
The traditional Chinese medicine enema has the advantages of simple raw material components, mild medicine property, suitability for early and middle stages of chronic renal failure, retention of the enema for 1 time every day during use, continuous use for 5 days, 3 days for each treatment course, total 4 treatment courses, reduced creatinine compared with that before treatment, 15% -39% of most cases, and remarkable curative effect.
Detailed Description
The traditional Chinese medicine composition for clysis has four core compositions: 28-32 parts of dandelion, 28-32 parts of red sage root and 14-16 parts of rhubarb. And on the basis of the core formula, three formulas formed by dialectically adding a plurality of raw medicines aiming at the disease difference, namely formula one: 28-32 parts of dandelion, 28-32 parts of salvia miltiorrhiza, 14-16 parts of rheum officinale and 11-13 parts of coptis chinensis; and the formula II: 28-32 parts of dandelion, 28-32 parts of red sage root, 14-16 parts of rheum officinale and 28-32 parts of oyster; and the formula III: 28-32 parts of dandelion, 28-32 parts of salvia miltiorrhiza, 14-16 parts of rheum officinale, 28-32 parts of oyster and 45-55 parts of astragalus membranaceus. The preparation method comprises decocting the above materials in water, and collecting decoction as enema.
The method comprises the following steps: herba Taraxaci is dried whole plant of herba Taraxaci, herba Taraxaci in Alkaloids or plants of the same genus; the Saviae Miltiorrhizae radix is dry root of Saviae Miltiorrhizae radix of Labiatae; radix et rhizoma Rhei is dry root and rhizome of Rheum palmatum (Pallet) of Polygonaceae or Rheum tanguticum Maxim. Or Rheum officinale Makino; rhizoma Coptidis is dried rhizome of rhizoma Coptidis or rhizoma Coptidis of Ranunculaceae; oyster is shell of oyster family, such as crassostrea gigas, crassostrea gigas or crassostrea gigas, and is obtained by removing flesh, cleaning, and sun drying; astragalus membranaceus is the dry root of Astragalus mongholicus bge or Astragalus membranaceus bge.
The application considers the theory of pathogenic factors and simultaneously considers the dispersion and purgation actions of the traditional Chinese medicine under the environment of the rectum, and is suitable for treating chronic renal failure, chronic kidney diseases and the like, and is suitable for attacking pathogenic factors and eliminating pathogenic factors. For the treatment, warm tonifying is contraindicated, mainly for cooling blood, removing blood stasis and clearing pathogenic toxin. The heat Yu Zhe is effective in promoting blood circulation and removing blood stasis for the damp obstruction and qi and blood stasis. Meanwhile, the gradual aggravation of 'blood stasis and toxin' is considered, and the chronic renal failure is the etiology and pathogenesis from light to heavy; chronic renal failure involves multiple viscera, including primary disease of spleen and kidney, middle stage liver and kidney, and late stage injury of multiple viscera, and forms multiple pathogenesis of kidney-essence deficiency and excessive symptoms such as internal movement of liver wind and internal sinking of pericardium. Therefore, the prescription is a raw material medicine with the effects of clearing and ventilating the spleen, kidney and liver, and activating blood and dissolving stasis.
Wherein, dandelion enters liver and stomach channels, clears away heat and toxic materials, reduces swelling and eliminates stagnation, promotes urination and relieves stranguria, and focuses on clearing away heat and dispersing thoroughly; red sage root, radix salviae miltiorrhizae, having the effects of inducing heart and liver meridian, removing blood stasis and relieving pain, promoting blood circulation and dredging meridian, clearing heart and relieving restlessness, rheum officinale, entering spleen, stomach, large intestine, liver and pericardium meridian, purging heat and dredging intestine, cooling blood and removing toxicity, removing blood stasis and dredging meridian, red sage root and large Huang Geyong, focusing on activating blood and removing blood stasis. In addition, coptidis rhizoma is added for patients with upper gastrointestinal discomfort; oyster can be added for patients with abdominal pain; radix astragali can be added for treating body deficiency and sweating. In the formula, dandelion, salvia miltiorrhiza and rheum officinale act synergistically, after enema therapy is used, on one hand, metabolic products in blood such as creatinine, urea nitrogen, molecular substances in polypeptide and the like can be removed through dispersion and ultrafiltration, and meanwhile, the effective components of the traditional Chinese medicine are inhaled into the blood; on the other hand, the tea has the functions of relieving the retention of body water, effectively eliminating edema, reducing creatinine, urea nitrogen, uric acid and the like through the purgation.
The application is illustrated and explained below by means of several examples, it being understood that the examples below are not intended to limit the application.
Example 1
Weighing the following raw materials in parts by weight: 30 parts of dandelion, 30 parts of red sage root and 15 parts of rheum officinale. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 2 times of that of the raw materials.
Example 2
Weighing the following raw materials in parts by weight: 28 parts of dandelion, 32 parts of salvia miltiorrhiza and 14 parts of rheum officinale. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 3 times of that of the raw materials.
Example 3
Weighing the following raw materials in parts by weight: 32 parts of dandelion, 28 parts of red sage root and 16 parts of rheum officinale. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 1 time of that of the raw materials.
Example 4
Weighing the following raw materials in parts by weight: 30 parts of dandelion, 30 parts of salvia miltiorrhiza, 15 parts of rheum officinale and 12 parts of coptis chinensis. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 2 times of that of the raw materials.
Example 5
Weighing the following raw materials in parts by weight: 28 parts of dandelion, 32 parts of salvia miltiorrhiza, 14 parts of rheum officinale and 13 parts of coptis chinensis. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 1 time of that of the raw materials.
Example 6
Weighing the following raw materials in parts by weight: 32 parts of dandelion, 28 parts of red sage root, 16 parts of rheum officinale and 11 parts of coptis chinensis. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 3 times of that of the raw materials.
Example 7
Weighing the following raw materials in parts by weight: 30 parts of dandelion, 30 parts of salvia miltiorrhiza, 15 parts of rheum officinale and 30 parts of oyster. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 2 times of that of the raw materials.
Example 8
Weighing the following raw materials in parts by weight: 32 parts of dandelion, 28 parts of red sage root, 16 parts of rheum officinale and 28 parts of oyster. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 3 times of that of the raw materials.
Example 9
Weighing the following raw materials in parts by weight: 28 parts of dandelion, 32 parts of salvia miltiorrhiza, 14 parts of rheum officinale and 32 parts of oyster. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 1 time of that of the raw materials.
Example 10
Weighing the following raw materials in parts by weight: 30 parts of dandelion, 30 parts of salvia miltiorrhiza, 15 parts of rheum officinale, 30 parts of oyster and 50 parts of astragalus membranaceus. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 2 times of that of the raw materials.
Example 11
Weighing the following raw materials in parts by weight: 28 parts of dandelion, 32 parts of salvia miltiorrhiza, 14 parts of rheum officinale, 32 parts of oyster and 45 parts of astragalus membranaceus. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 3 times of that of the raw materials.
Example 12
Weighing the following raw materials in parts by weight: 32 parts of dandelion, 28 parts of red sage root, 16 parts of rheum officinale, 28 parts of oyster, and 55 parts of astragalus membranaceus. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 1 time of that of the raw materials.
Comparative example
On the basis of the example 1, the taste of the crude drug is reduced; namely the raw material medicine comprises the following components in parts by weight: 30 parts of red sage root and 15 parts of rhubarb. Decocting the raw materials with water, and collecting decoction as enema, wherein the weight of the obtained enema is 2 times of that of the raw materials.
Clinical materials
1. General data
All cases are derived from early and middle stage chronic renal failure patients who receive and treat in 2018-2021. 200 people total, of which 82 men and 118 women, age 50-70 years, average 65.35 years; the disease course is 0.5 to 21 years, and the average time is 12.20 years; the weight is 45-90 kg, and the average weight is 55.42kg. Wherein, the primary disease: 66 cases of chronic glomerulonephritis, 96 cases of diabetic nephropathy and 38 cases of hypertensive nephropathy. Stage of disease: 36 cases of renal insufficiency, 114 cases of renal insufficiency, and 50 cases of renal failure.
All cases are sequentially and randomly divided into 10 groups according to the sequence of the time of treatment, 20 cases are respectively used in each group, and the medicines prepared in the previous examples 1, 4, 7, 10 and comparative example are respectively used in each group. Each medicine adopts two administration modes of conventional oral administration and traditional Chinese medicine clysis; the oral administration mode is that the medicine liquid is taken twice a day and a night, 50mL of medicine liquid is taken each time, the enema mode is that the enema is reserved for 1 time a day, 100mL of medicine liquid is taken each time, 5 days are taken as a treatment course, and each treatment course is 3 days apart, and the total treatment course is 4. The efficacy was counted and analyzed after 4 treatment courses. The specific case of the packet is shown in table 1. The general clinical data are statistically processed, so that each parameter among groups has good balance, no significant difference and good comparability.
TABLE 1 case grouping Condition
2. Case inclusion criteria
(1) Meets the Western diagnosis standard of chronic renal failure; (2) is in chronic renal insufficiency compensatory stage, decompensation stage and chronic renal failure stage; (3) non-dialysis patients with effectively controlled exacerbation factors such as hypertension, electrolyte disorder, acidosis, bacterial virus-induced infection and the like; (4) age characteristics 18 to 70 years old; (5) the disease is caused by chronic nephritis, chronic pyelonephritis, diabetic nephropathy, hypertensive nephropathy, etc.
3. Therapeutic effect criterion
The therapeutic effect criteria include clinical symptoms and creatinine, the criteria are shown in Table 2, and the clinical symptom score criteria are shown in Table 3.
TABLE 2 determination of curative effect of chronic renal failure (meeting both (1) and (2))
| CRF therapeutic effect determination | (1) Integration of clinical symptoms | (2) Blood creatinine (Scr) |
| Is remarkable in | The reduction is more than or equal to 60 percent | The reduction is more than or equal to 20 percent |
| Effective and effective | The reduction is more than or equal to 30 percent | The reduction is more than or equal to 10 percent |
| Stabilization | Improvement of clinical symptoms and reduction of integral<30％ | No increase or decrease<10％ |
| Invalidation of | No improvement or exacerbation of clinical symptoms | Increase in |
TABLE 3 score criteria for clinical symptom score
4. Therapeutic results
The test results and scoring results were statistically analyzed using SPSSl6.0, data were usedIndicating that the measurement data is t-checked and the count data is x 2 The difference is statistically significant when P < 0.05 is detected. In experimental examples 1 to 8, the curative effect of the enema group is higher than that of the oral group (P is less than 0.05); in comparative examples 1 and 2, the effects of the enema group and the oral group were not significantly different (P > 0.05). The results are shown in tables 4 and 5.
Table 4, comparison of total efficacy before and after treatment [ n (%) ]
| Group of | n | Is remarkable in | Effective and effective | Stabilization | Invalidation of | Total effective rate (%) |
| Experimental example 1 | 20 | 1 | 4 | 7 | 8 | 60 |
| Experimental example 2 | 20 | 6 | 6 | 7 | 1 | 95 |
| Experimental example 3 | 20 | 2 | 4 | 7 | 7 | 65 |
| Experimental example 4 | 20 | 7 | 6 | 4 | 3 | 85 |
| Experimental example 5 | 20 | 0 | 4 | 6 | 10 | 50 |
| Experimental example 6 | 20 | 6 | 6 | 5 | 3 | 85 |
| Experimental example 7 | 20 | 1 | 5 | 6 | 8 | 60 |
| Experimental example 8 | 20 | 5 | 7 | 6 | 2 | 90 |
| Comparative example 1 | 20 | 0 | 6 | 5 | 9 | 55 |
| Comparative example 2 | 20 | 1 | 5 | 6 | 8 | 60 |
TABLE 5 comparison of blood creatinine (Scr) test results before and after treatment (. Mu.mol/L)
| Experimental example 1 | Experimental example 2 | Experimental example 3 | Experimental example 4 | Experimental example 5 | |
| Before treatment | 292.42±107.31 | 296.50±113.51 | 304.64±111.49 | 325.10±121.58 | 291.46±107.11 |
| After treatment | 277.24±106.83 | 241.32±99.29 | 282.87±95.98 | 264.01±83.22 | 275.79±108.05 |
| Experimental example 6 | Experimental example 7 | Experimental example 8 | Comparative example 1 | Comparative example 2 | |
| Before treatment | 283.94±119.51 | 338.23±113.17 | 292.94±107.45 | 301.87±116.78 | 297.38±115.11 |
| After treatment | 237.60±81.46 | 318.39±101.68 | 249.61±81.51 | 281.13±95.16 | 277.51±97.13 |
As shown in tables 4 and 5, the medicament of the application can effectively reduce creatinine, can be applied to the early treatment of chronic renal failure, and has better curative effect after clysis than the conventional oral administration mode; the four formulas have no obvious difference in curative effect, so that the traditional Chinese medicine formulas for clysis can play a role in reducing creatinine in the process of treating chronic renal failure.
Claims (2)
1. A preparation method of traditional Chinese medicine enema is characterized in that the preparation method takes the following enema traditional Chinese medicines as raw materials, decoction is reserved after water decoction and is used as enema liquid, and the weight of the obtained enema liquid is 1-3 times of that of the raw materials; wherein the traditional Chinese medicine for clysis comprises the following components in parts by weight: 30 parts of dandelion, 30 parts of red sage root and 15 parts of rheum officinale.
2. The use of the traditional Chinese medicine enema prepared by the preparation method of claim 1 in preparing medicines for treating chronic renal failure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210554029.9A CN115040565B (en) | 2022-05-20 | 2022-05-20 | Enema traditional Chinese medicine for reducing creatinine and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210554029.9A CN115040565B (en) | 2022-05-20 | 2022-05-20 | Enema traditional Chinese medicine for reducing creatinine and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115040565A CN115040565A (en) | 2022-09-13 |
| CN115040565B true CN115040565B (en) | 2023-11-03 |
Family
ID=83160277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210554029.9A Active CN115040565B (en) | 2022-05-20 | 2022-05-20 | Enema traditional Chinese medicine for reducing creatinine and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115040565B (en) |
-
2022
- 2022-05-20 CN CN202210554029.9A patent/CN115040565B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 中药结肠透析治疗慢性肾衰竭的临床研究;金丽霞等;中医药学报;-;第39卷(第04期);113-115 * |
| 爱西特联合中药保留灌肠治疗慢性肾衰竭疗效观察;施钰琳等;湖北中医杂志;-;第30卷(第05期);40-41 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115040565A (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN104857359A (en) | Medicinal composition for treating piglet dysentery and preparation method of medicinal composition | |
| CN112138054A (en) | Chinese herbal medicine preparation for treating hemorrhoids and preparation method thereof | |
| CN102641430A (en) | Traditional Chinese medicine decoction for treating diabetic nephropathy (DN) | |
| CN115040565B (en) | Enema traditional Chinese medicine for reducing creatinine and preparation method and application thereof | |
| CN111481638A (en) | Traditional Chinese medicine enema preparation for treating ulcerative colitis and preparation method thereof | |
| CN103432485B (en) | Chinese medicinal preparation for treating urinary calculus and preparation method | |
| CN104383155A (en) | Chinese medicinal composition for treating constipation | |
| CN111632110B (en) | Traditional Chinese medicine enema composition for treating ulcerative colitis and preparation method and application thereof | |
| CN104000938B (en) | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof | |
| CN1418674A (en) | Medicine compositions for treating acne, and its prepn. method | |
| CN111265554A (en) | Application of antiviral compound composition in resisting HIV virus, SARS virus and leukemia virus | |
| CN115607644B (en) | Traditional Chinese medicine composition for treating IgA nephropathy and preparation method thereof | |
| CN105687437A (en) | Traditional Chinese medicine composition for treating prostatitis | |
| CN104288579A (en) | Traditional Chinese medicine for treating chronic nephritis and preparation method thereof | |
| CN115814031B (en) | Heat-clearing and detoxicating composition for treating gouty arthritis | |
| CN103961562A (en) | Concentrated oral solution for treating recurrent oral ulcer by type of fire excess from yin deficiency | |
| CN103479915B (en) | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof | |
| CN108926672B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN116808145A (en) | Traditional Chinese medicine composition for treating chronic kidney disease | |
| CN104825756A (en) | Traditional Chinese medicine composition for treating chronic renal failure | |
| CN117224624A (en) | Traditional Chinese medicine composition for preventing and/or treating renal edema and preparation method thereof | |
| CN117205258A (en) | Traditional Chinese medicine composition for preventing and treating liver injury as well as preparation method and application thereof | |
| CN103721226B (en) | A kind ofly prevent and treat Chinese medicine composition of symptom of digestive tract chronic kidney hypofunction and preparation method thereof | |
| CN104147199B (en) | One is used for the treatment of uremic Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |